Further long-term studies are required to analyze the efficiency, different types of prognostic factors.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:To review the prognostic factors in uterine cervix adenocarcinoma In this retrospective study, we identified studies which were obtained from a medline search from 1987 through 2004 and published in the English language regarding prognostic factors influencing survival and recurrences in cervical adenocarcinoma.
📊
Temel Bulgular & Veri:Clinicopathological prognostic factors, including patient age, clinical stage, tumor histopathology, lymph node metastasis, grade, tumor size, the depth of tumor invasion, lymphovascular space invasion, angiogenesis and molecular prognostic factors, including DNA flow cytometry, DNA content, estrogen and progesteron receptors, p53, VEGF, interleukin-8, tumour necrosis factor-?, and platelet-derived endothelial cell growth factor, cyclooxygenase-2, ß-catenin, mitotic index/apoptotic index, c-erbB-2 and proliferating cell nuclear antigen labelling index, Bcl-2, caspases, CA-125 were investigated.
💡
Sonuç & Katkı:Further long-term studies are required to analyze the efficiency, different types of prognostic factors.
To review the prognostic factors in uterine cervix adenocarcinoma In this retrospective study, we identified studies which were obtained from a medline search from 1987 through 2004 and published in the English language regarding prognostic factors influencing survival and recurrences in cervical adenocarcinoma. Clinicopathological prognostic factors, including patient age, clinical stage, tumor histopathology, lymph node metastasis, grade, tumor size, the depth of tumor invasion, lymphovascular space invasion, angiogenesis and molecular prognostic factors, including DNA flow cytometry, DNA content, estrogen and progesteron receptors, p53, VEGF, interleukin-8, tumour necrosis factor-?, and platelet-derived endothelial cell growth factor, cyclooxygenase-2, ß-catenin, mitotic index/apoptotic index, c-erbB-2 and proliferating cell nuclear antigen labelling index, Bcl-2, caspases, CA-125 were investigated. In many studies using a wide variety of clinicopathological factors and tumor markers have been analyzed as potential prognostic predictors in patients with cervical adenocarcinoma. Unfortunately, the results of these studies are in part fragmentary and such of little practical value. Further long-term studies are required to analyze the efficiency, different types of prognostic factors.
Smith HO, Tiffany MF, Quails CR et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States-a 24-year population-based study. Gynecol Oncol 2000; 78:97-105
Brand E, Berek JS, Hacker NF. Controversies in the management of cervical adenocarcinoma. Obstet Gynecol 1988; 71:261-9
Soisson AP, Soper JT, Berchuck A et al. Radical hysterectomy in obese women. Obstet Gynecol 1992; 80:940-3
Jorgensen RG, Russo L, Mattioli L et al. Early detection of vascular dysfunction in type I diabetes.Diabetes 1988; 37:292-6
Wilde MI, Balfour JA. Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations. Drugs 1995; 50:364-95
Fujiwara H, Tortolero-Luna G, Mitchell MF et al. Adenoczarcinoma of the cervix. Expression and clinical significance of estrogen and progesterone receptors. Cancer 1997; 79:505-12
Chen YJ, Wang LS, Wang PH et al. High cyclooxygenase- 2 expression in cervical adenocarcinomas. Gynecol Oncol 2003; 88:379-85
Eifel PJ, Burke TW, Morris M et al. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995; 59:38-44
Baalbergen A, Ewing-Graham PC, Hop WC et al. Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol 2004; 92:262-7
Ishikawa H, Nakanishi T, Inoue T et al. Prognostic factors of adenocarcinoma of the uterine cervix. Gynecol Oncol 1999; 73:42-6
Davy ML, Dodd TJ, Luke CG et al. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstet Gynecol 2003; 101:38-45. 12.Barillot I, Horiot JC, Pigneux J et al. Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors. Int J Radiat Oncol Biol Phys 1997; 38:969-78
Chen RJ, Chang DY, Yen ML et al. Prognostic factors of primary adenocarcinoma of the uterine cervix. Gynecol Oncol 1998; 69:157-64
Lea JS, Sheets EE, Wenham RM et al. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol 2002; 84:115-9. 15.Lai CH, Hsueh S, Hong JH et al. Are adenocarcinomas and adenosquamous carcinomas different from squamous carcinomas in stage IB and II cervical cancer patients undergoing primary radical surgery? Int J Gynecol Cancer 1999; 9:28-36. 16.Kaspar HG, Dinh TV, Doherty MG et al. Clinical implications of tumor vol